{"text": ["AbbVie's", "Psoriasis", "Drug", "Skyrizi", "Gets", "First", "Approval", "in", "Japan"], "created_at": "2019-03-26 17:09:54"}
{"text": ["AbbVie's", "Psoriasis", "Drug", "Skyrizi", "Gets", "First", "Approval", "in", "Japan"], "created_at": "2019-03-26 17:09:54"}
{"text": ["Health", "Care", "Select", "Sector", "SPDR", "Fund", "Experiences", "Big", "Inflow"], "created_at": "2019-03-26 16:10:42"}
{"text": ["Health", "Care", "Select", "Sector", "SPDR", "Fund", "Experiences", "Big", "Inflow"], "created_at": "2019-03-26 16:10:42"}
{"text": ["AbbVie's", "Psoriasis", "Drug", "Skyrizi", "Gets", "First", "Approval", "in", "Japan"], "created_at": "2019-03-26 15:18:03"}
{"text": ["Were", "Hedge", "Funds", "Right", "About", "AbbVie", "Inc", "(ABBV)?"], "created_at": "2019-03-26 13:06:59"}
{"text": ["The", "Daily", "Biotech", "Pulse:", "Japanese", "Cheer", "For", "AbbVie,", "Myokardia", "Offering,", "CytomX", "CFO", "Departs"], "created_at": "2019-03-26 11:36:32"}
{"text": ["AbbVie", "Announces", "First", "Regulatory", "Approval", "of", "SKYRIZI\u2122", "(risankizumab)", "for", "the", "Treatment", "of", "Plaque", "Psoriasis,", "Generalized", "Pustular", "Psoriasis", "and", "Erythrodermic", "Psoriasis", "and", "Psoriatic", "Arthritis", "in", "Japan"], "created_at": "2019-03-26 05:00:00"}
{"text": ["AbbVie", "(ABBV)", "Dips", "More", "Than", "Broader", "Markets:", "What", "You", "Should", "Know"], "created_at": "2019-03-26 00:10:05"}
{"text": ["AbbVie", "(ABBV)", "Dips", "More", "Than", "Broader", "Markets:", "What", "You", "Should", "Know"], "created_at": "2019-03-26 00:10:05"}
